Fate Therapeutics (Nasdaq: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation cellular immunotherapies for cancer and immune disorders. Our first-in-class cell therapy products undergoing clinical development today utilize healthy donor cells, which we modify ex vivo using pharmacologic modulators, such as small molecules, to improve the cells’ biological properties and therapeutic function. We are also pioneering a revolutionary approach to cell therapy – we use renewable master induced pluripotent stem cell (iPSC) lines generated from our proprietary iPSC product platform to derive cell therapy products that can be delivered off-the-shelf for the treatment of a large number of patients.
Our cells of interest are the cells of the immune system. Our cell therapy product pipeline is comprised of immuno-oncology programs, including off-the-shelf NK- and T-cell products derived from master iPSC lines, and immuno-regulatory programs, including products to prevent life-threatening complications in patients undergoing hematopoietic cell transplantation and to promote immune tolerance in patients with autoimmune disease.
Guiding Cells to Improve Life